<DOC>
	<DOC>NCT00918346</DOC>
	<brief_summary>The objective of this study is to investigate the pharmacodynamics (as expressed in intraocular pressure [IOP]) of two formulations of tafluprost 0.0015% eyedrops (preserved and unpreserved) in patients with open-angle glaucoma or ocular hypertension. The primary aim of this study is to show that IOP reduction between the two formulations is equivalent at the end of the 4 week treatment period.</brief_summary>
	<brief_title>Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Age 18 years or more A diagnosis of open angle glaucoma or ocular hypertension Prior use of prostaglandin(s) Intra ocular pressure of 2234 mmHg in at least one eye Females who are pregnant, nursing or planning a pregnancy, or females of childbearing potential who are not using a reliable method of contraception Previous participation in any clinical trial in which tafluprost was an investigational drug or use of contact lenses at screening or during the study Presence of any abnormality or significant illness that could be expected to interfere with the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Ocular hypertension</keyword>
</DOC>